In this newly created position, he reports to the CEO and is a member of the group executive committee. Sartorius Group highest-level management team is now composed of six individuals, including the executives of both Sartorius AG and the subgroup Sartorius Stedim Biotech.

The company said the new management appointment is a key component in the further strategic and operational development of its laboratory business. The major goals of this initiative are the expansion into strategic, fast growing market segments, the targeted extension of the product portfolio and the reinforcement of direct sales organizations in key markets, the company said in a press release.

Baly has more than 35 years of sales and managerial experience for the U.S.-based pharmaceutical supplier Millipore Corporation, which was acquired by Merck KGaA in 2010. From 2005 to 2008, he was president of the $700 millions Bioscience Division. In 2009, he became CEO of Accelerator Sciences, a U.S. investment firm backed by private equity. Baly is a dual citizen of France and the United States, and holds a degree as a pharmacist from the Louis Pasteur University in Strasbourg, France.